Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. (Q35796527)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 2 October 2015

Language	Label	Description	Also known as
English	Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.	scientific article published on 2 October 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

C C Bjorklund

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

L Lu

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

J Kang

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

P R Hagner

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

C G Havens

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

M Amatangelo

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

M Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Y Ren

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

S Couto

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

M Breider

10

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Y Ning

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

A K Gandhi

12

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

T O Daniel

13

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

R Chopra

14

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

A Klippel

15

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

A G Thakurta

16

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

2 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Blood Cancer Journal

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

e354

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

copyright license

Creative Commons Attribution 4.0 International

1 October 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Addiction to c-MYC in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Identification of a primary target of thalidomide teratogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Roles of TGFbeta in metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

IRF4 addiction in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Critical function of Ikaros in controlling Aiolos gene expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Molecular pathogenesis and a consequent classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Haematopoietic cell-fate decisions, chromatin regulation and ikaros

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

The role of the Ikaros gene in lymphocyte development and homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

11 July 2018

Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

25 September 2018

Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

25 September 2018

Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4635186

25 September 2018

Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26430725

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BCJ.2015.66

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35796527&oldid=2197755796"